Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

May 14, 2024

BUY
$0.74 - $15.01 $52,090 - $1.06 Million
70,393 Added 52.0%
205,755 $144,000
Q3 2022

Nov 10, 2022

BUY
$0.74 - $15.01 $52,090 - $1.06 Million
70,393 Added 52.0%
205,755 $0
Q2 2022

May 14, 2024

BUY
$0.71 - $2.43 $96,107 - $328,929
135,362 New
135,362 $133,000
Q2 2022

Aug 15, 2022

SELL
$0.71 - $2.43 $283,977 - $971,922
-399,968 Reduced 74.71%
135,362 $133,000
Q1 2022

May 16, 2022

SELL
$2.31 - $5.13 $1.18 Million - $2.62 Million
-510,095 Reduced 48.79%
535,330 $1.27 Million
Q4 2021

Feb 14, 2022

SELL
$4.45 - $8.09 $1.41 Million - $2.56 Million
-315,869 Reduced 23.2%
1,045,425 $4.98 Million
Q3 2021

Nov 10, 2021

BUY
$6.94 - $8.85 $9.45 Million - $12 Million
1,361,294 New
1,361,294 $10.7 Million

About CURIS INC


  • Ticker CRIS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 91,814,704
  • Market Cap $393M
  • Description
  • Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myel...
More about CRIS
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.